Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | cyclin dependent kinase 7 (cdk7), putative | 0.0163685 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.00116054 | 0.000868153 | 0.0144822 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.00205978 | 0.059946 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.00205978 | 0.059946 | 0.057984 |
Schistosoma mansoni | cytochrome P450 reductase | 0.00205978 | 0.059946 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.00205978 | 0.059946 | 1 |
Leishmania major | cytochrome P450 reductase, putative | 0.00188972 | 0.0487736 | 0.806916 |
Echinococcus multilocularis | serine:threonine protein kinase NLK | 0.00117903 | 0.00208281 | 0.0347448 |
Brugia malayi | FAD binding domain containing protein | 0.00205978 | 0.059946 | 1 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.00205978 | 0.059946 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.00205978 | 0.059946 | 1 |
Loa Loa (eye worm) | AGC/PDK1 protein kinase | 0.00117903 | 0.00208281 | 0.0347448 |
Brugia malayi | flavodoxin family protein | 0.00205978 | 0.059946 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.00205978 | 0.059946 | 1 |
Entamoeba histolytica | cell division protein kinase 2, putative | 0.00117903 | 0.00208281 | 1 |
Entamoeba histolytica | protein kinase domain containing protein | 0.00117903 | 0.00208281 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.00205978 | 0.059946 | 1 |
Brugia malayi | Protein kinase domain containing protein | 0.00117903 | 0.00208281 | 0.0347448 |
Echinococcus granulosus | mitogen activated protein kinase 15 | 0.00117903 | 0.00208281 | 0.0347448 |
Trichomonas vaginalis | sulfite reductase, putative | 0.00205978 | 0.059946 | 1 |
Echinococcus granulosus | methionine synthase reductase | 0.0013306 | 0.0120406 | 0.200857 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0013306 | 0.0120406 | 0.200857 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.00205978 | 0.059946 | 1 |
Brugia malayi | cyclin-dependent kinase 7 homolog | 0.00117903 | 0.00208281 | 0.0347448 |
Schistosoma mansoni | protein kinase | 0.00117903 | 0.00208281 | 0.0347448 |
Toxoplasma gondii | cell-cycle-associated protein kinase, putative | 0.0152212 | 0.924623 | 0.5 |
Leishmania major | p450 reductase, putative | 0.00205978 | 0.059946 | 1 |
Echinococcus granulosus | serine:threonine protein kinase NLK | 0.00117903 | 0.00208281 | 0.0347448 |
Echinococcus multilocularis | cyclin dependent kinase 9 | 0.00117903 | 0.00208281 | 0.0347448 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.00205978 | 0.059946 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.00188972 | 0.0487736 | 1 |
Loa Loa (eye worm) | CMGC/CDK/CRK7 protein kinase | 0.00117903 | 0.00208281 | 0.0347448 |
Plasmodium falciparum | MO15-related protein kinase | 0.0163685 | 1 | 1 |
Echinococcus multilocularis | methionine synthase reductase | 0.0013306 | 0.0120406 | 0.200857 |
Plasmodium vivax | flavodoxin domain containing protein | 0.00188972 | 0.0487736 | 0.0467882 |
Schistosoma mansoni | serine/threonine protein kinase | 0.00117903 | 0.00208281 | 0.0347448 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.00205978 | 0.059946 | 0.5 |
Echinococcus multilocularis | Cell division cycle 2 protein kinase | 0.00117903 | 0.00208281 | 0.0347448 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.00205978 | 0.059946 | 1 |
Brugia malayi | Cell division protein kinase 2 | 0.00117903 | 0.00208281 | 0.0347448 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.00205978 | 0.059946 | 1 |
Giardia lamblia | Hypothetical protein | 0.00188972 | 0.0487736 | 1 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.00188972 | 0.0487736 | 0.806916 |
Trypanosoma cruzi | p450 reductase, putative | 0.00205978 | 0.059946 | 1 |
Echinococcus granulosus | cyclin dependent kinase 9 | 0.00117903 | 0.00208281 | 0.0347448 |
Echinococcus granulosus | Cell division cycle 2 protein kinase | 0.00117903 | 0.00208281 | 0.0347448 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0013306 | 0.0120406 | 0.200857 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.00205978 | 0.059946 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.00205978 | 0.059946 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.00205978 | 0.059946 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0013306 | 0.0120406 | 0.5 |
Schistosoma mansoni | serine/threonine kinase | 0.00117903 | 0.00208281 | 0.0347448 |
Loa Loa (eye worm) | haspin protein kinase | 0.00117903 | 0.00208281 | 0.0347448 |
Brugia malayi | FAD binding domain containing protein | 0.0013306 | 0.0120406 | 0.200857 |
Loa Loa (eye worm) | hypothetical protein | 0.00205978 | 0.059946 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 10.55 uM | Antiplasmodial activity against erythrocytic stage of chloroquine - and pyrimethamine-resistant Plasmodium falciparum K1 assessed as [3H]hypoxanthine incorporation after 48 hrs | ChEMBL. | 19564359 |
IC50 (functional) | = 21.28 uM | Antitrypanosomal activity against Trypanosoma brucei rhodesiense ST1B900 trypomastigote infected in NMR1 mouse assessed as inhibition of parasitemia at 50 mg/kg, ip administered on day 3 post infection for 4 days | ChEMBL. | 19564359 |
IC50 (functional) | = 23.25 uM | Antileishmanial activity against Leishmania donovani MHOM/ET/67/L82 amastigote after 72 hrs | ChEMBL. | 19564359 |
IC50 (functional) | = 46.15 uM | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C2C4 trypomastigote after 48 hrs | ChEMBL. | 19564359 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | 19564359 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.